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Despite significant advances in the treatment of prematurity including antenatal steroids, 
advanced mechanical ventilation strategies, and exogenous surfactant, the mortality and 









extremely low gestational age newborns (ELGANs) defined as < 28 weeks estimated 
gestational age(EGA), is extremely high1. A radical paradigm shift in the treatment of extreme 
prematurity would be to re-create the intra-uterine environment using an extracorporeal Artificial 
Placenta(AP). 
 In this issue, Metelo-Coimbra and Roncon-Albuquerque review recent advances in the 
field and assess barriers to clinical translation2. From the outset, it should be acknowledged that 
although there is a large number of premature births worldwide (defined as < 37 weeks EGA), 
outcomes have substantially improved for infants > 28 weeks EGA. Apart from some specific 
congenital anomalies like congenital diaphragmatic hernia, the Artificial Placenta is intended for 
the treatment of ELGANS who experience the most complications of prematurity and whose 
outcome remains poor. 
The authors focus on lung immaturity and provide substantial evidence of the iatrogenic 
effects of mechanical ventilation on both lung injury and the deleterious cardiovascular effects2. 
It’s worth noting that although ELGANS are predisposed to interventricular hemorrhage(IVH) 
given their immature germinal matrix, mechanical ventilation has been implicated in the 
pathogenesis of IVH by increasing intrathoracic and intracranial pressure with every breath3. 
The ELGANs who are never subjected to positive airway pressure have fewer complications of 
prematurity. An appreciation of the deleterious effects of mechanical ventilation and high oxygen 
concentrations on premature lungs has led to a dramatic shift towards less invasive ventilator 
strategies for premature infants. Although this strategy appears promising for some patients4, 
there is still a subset of ELGANS that cannot maintain adequate gas exchange with the most 
invasive ventilator strategies.   
Although the pulmonary system is critical to initial survival and long-term pulmonary 
morbidity is high amongst survivors, there are other significant complications of ELGANs that 
warrant consideration. Predictable and unsolved complications associated with prematurity 









prematurity(ROP), and sepsis. Our current inability to prevent these complications relates both 
to organ immaturity and conventional treatment strategies such as positive pressure ventilation, 
that have historically been developed for full term infants. To potentially solve these problems, 
the Artificial Placenta must not only recreate the fetal milieu and provide life-sustaining functions 
such as adequate gas exchange and fetal hemodynamic stability, but it should also protect 
against organ trauma and allow the normal developmental pathways to occur.  
An artificial placenta may appear far beyond the reach of modern science, but the idea 
of creating a life support system to maintain growing fetuses in a womb-like environment with 
extracorporeal support was first investigated 60 years ago!  Metelo-Coimbra and Roncon-
Albuquerque provide a succinct review of AP terminology and history of milestones2. Since 
fetuses normally develop with extracorporeal support, it should perhaps not surprise us that 
researchers were drawn to this concept shortly after the successful introduction of cardio-
pulmonary bypass. For historians of science, it is noteworthy that researchers were on the right 
path, but got derailed many times due to the state of biomedical technology and insufficient 
knowledge of the physiology of premature infants. In my view, the history of the development of 
the Artificial Placenta is marked by many experimental failures with episodic successes. Despite 
incremental success, many research groups abandoned this work as progress was being made 
with antenatal steroids, exogenous surfactant, advanced mechanical ventilation strategies, and 
ECMO for term and near-term infants.  
An appreciation of the unsolved problems of extreme prematurity coupled with recent 
advances detailed by the authors2 has led to a resurgence of work on the Artificial Placenta. The 
fetal lamb is the best model, and the lamb gestational age which corresponds to ELGAN lungs 
is 118 days gestation (term = 145 days). Although the AP is promising and has the potential to 
radically change the treatment of prematurity, several obstacles remain. As the authors point 
out2, the first issue is the most effective ECLS configuration. A simple pumpless AV-ECLS 









term survival and declining cardiac function5. Despite cannulation of the umbilical arteries to the 
sheep aorta (to obviate vessel spasm) and adding a pump, matching extracorporeal flow to 
systemic flow is very difficult (the native placenta does this automatically). In addition, given the 
tortuosity, size, and spasm associated with human umbilical arteries, we transitioned to a pump-
driven VV-ECLS model with inflow via the umbilical vein and outflow via the jugular vein. This 
approach provides 7 days of support with excellent gas exchange and hemodynamic stability6. 
With current technology, we believe this strategy is clinically translatable to extremely premature 
infants.  
As mentioned previously, the AP strategy will require long-term support (2-4 weeks in 
humans) and demonstration that organs are maturing and protected from trauma. This 
corresponds to 10-14 days in the 118 day lamb model. As such, an in-depth study of lung 
development, long-term support, and weaning to a ventilator and air breathing will be required. 
A crucial aspect of lung development will be the airway strategy during AP support. In our early 
work, the fetal lambs were submerged in a warmed ‘amniotic bath’ effectively re-creating the 
intrauterine environment5,7. While appealing in some regards, there are infection and patient 
access issues with this approach. More recently, we have been intubating the fetal lambs, filling 
them with amniotic fluid or Perflubron and either capping the endotracheal tube or maintaining 
5-8 cm H2O pressure.  It is possible to harness the power of mechanotransduction with this 
approach and possibly accelerate lung growth8,9. 
Apart from lung development which is crucial during AP support, other vulnerable 
premature organs need to be examined. Brain perfusion, function, and development are critical 
to understand. Although the sheep is not a good model for IVH, brain physiology and evidence 
of white matter injury can be assessed. With a high incidence of NEC in premature infants, 
optimal nutrition and perfusion of the gastrointestinal system warrants investigation.  Long term 
survivors of the AP should be examined for evidence of retinopathy of prematurity. Lastly, renal 









As a general rule, extracorporeal support is reserved for infants ≥ 34 weeks EGA due to 
a higher rate of IVH in extremely premature infants. The authors point out the feasibility of 
‘preemie ECMO’ in infants from 29-33 weeks2, but ELGANs would have prohibitively high rates 
of IVH. As such, a critical barrier to clinical application will be the development of non-
thrombogenic surfaces that will obviate the need for anti-coagulation10,11. Lastly, clinical 
application will require a clinical prognostication tool to select premature infants at the highest 
risk for mortality on the first day of life12.  
Given recent advances and ongoing work, we believe that the Artificial Placenta will be 
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